SenzaGen Past Earnings Performance
Past criteria checks 0/6
SenzaGen has been growing earnings at an average annual rate of 5.6%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 50% per year.
Key information
5.6%
Earnings growth rate
15.2%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | 50.0% |
| Return on equity | -32.7% |
| Net Margin | -44.3% |
| Next Earnings Update | 15 May 2024 |
Recent past performance updates
Recent updates
We're Not Very Worried About SenzaGen's (STO:SENZA) Cash Burn Rate
Nov 28
We're Hopeful That SenzaGen (STO:SENZA) Will Use Its Cash Wisely
Jul 30Companies Like SenzaGen (STO:SENZA) Are In A Position To Invest In Growth
Apr 16Here's Why We're Not Too Worried About SenzaGen's (STO:SENZA) Cash Burn Situation
Jan 01Revenue & Expenses BreakdownBeta
How SenzaGen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 50 | -22 | 46 | 4 |
| 30 Sep 23 | 48 | -23 | 44 | 5 |
| 30 Jun 23 | 45 | -24 | 43 | 6 |
| 31 Mar 23 | 44 | -24 | 41 | 8 |
| 31 Dec 22 | 42 | -25 | 39 | 9 |
| 30 Sep 22 | 36 | -28 | 40 | 8 |
| 30 Jun 22 | 30 | -31 | 41 | 7 |
| 31 Mar 22 | 23 | -31 | 39 | 6 |
| 31 Dec 21 | 15 | -31 | 37 | 4 |
| 30 Sep 21 | 12 | -30 | 33 | 3 |
| 30 Jun 21 | 9 | -28 | 30 | 3 |
| 31 Mar 21 | 9 | -28 | 30 | 3 |
| 31 Dec 20 | 8 | -27 | 29 | 3 |
| 30 Sep 20 | 6 | -38 | 31 | 4 |
| 30 Jun 20 | 5 | -48 | 33 | 6 |
| 31 Mar 20 | 4 | -49 | 34 | 7 |
| 31 Dec 19 | 3 | -50 | 35 | 8 |
| 30 Sep 19 | 5 | -37 | 34 | 6 |
| 30 Jun 19 | 6 | -23 | 34 | 3 |
| 31 Mar 19 | 8 | -19 | 34 | 2 |
| 31 Dec 18 | 10 | -16 | 33 | 0 |
| 30 Sep 18 | 10 | -15 | 32 | 0 |
| 30 Jun 18 | 11 | -13 | 30 | 0 |
| 31 Mar 18 | 11 | -13 | 30 | 0 |
| 31 Dec 17 | 11 | -13 | 29 | 0 |
| 30 Sep 17 | 9 | -12 | 25 | 0 |
| 30 Jun 17 | 7 | -12 | 20 | 0 |
| 31 Mar 17 | 5 | -10 | 16 | 0 |
| 31 Dec 16 | 3 | -9 | 12 | 0 |
| 31 Dec 15 | 4 | -3 | 6 | 0 |
| 31 Dec 14 | 2 | 0 | 2 | 0 |
Quality Earnings: SENZA is currently unprofitable.
Growing Profit Margin: SENZA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SENZA is unprofitable, but has reduced losses over the past 5 years at a rate of 5.6% per year.
Accelerating Growth: Unable to compare SENZA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SENZA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: SENZA has a negative Return on Equity (-32.68%), as it is currently unprofitable.